Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

Fig. 3

In vivo effects of ADM knockdown on the TMZ treatment of glioma A A subcutaneous tumor model was established in nude mice as described, and part of the model mice received TMZ treatment or ADM knockdown and the images of the tumors were displayed. B, C Tumor weight and volume were examined. D The histopathological characteristics of the tumors were examined by hematoxylin and eosin (H&E) staining. E The level of proliferation marker protein Ki-67 was detected in the tumors by immunohistochemistry (IHC) staining. F The protein levels of ADM, cleaved caspase 3, pro caspase 3, cleaved caspase 9, pro-caspase 9, Bax, Bcl-2, p-Akt, Akt, p-Erk1/2, Erk1/2 and cleaved PARP in the tumors were determined by Immunoblotting

Back to article page